Clinical Trial

Horizon Two: HR NDMM (MMRC-100)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 7 locations 2026-06-11
Trial Details
NCT Number NCT07053436
Lead Sponsor Multiple Myeloma Research Consortium
Conditions High Risk Newly Diagnosed Multiple Myeloma
Enrollment 300 participants
Start Date 2026-04-30
Primary Completion 2035-10-01 (estimated)
Study Completion 2035-10-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-10